Edwards Lifesciences (NYSE:EW) shares surged over 7% after the company delivered second-quarter earnings that topped estimates, driven by robust performance across its product segments.
Adjusted EPS came in at $0.67, ahead of the $0.62 consensus, while revenue grew 11.9% year-over-year to $1.53 billion, surpassing the $1.49 billion projection. On a comparable basis, adjusted revenue rose 10.6% versus the prior year.
Following the upbeat results, Edwards raised its full-year 2025 sales growth forecast to 9-10% from 8-10%, and lifted its TAVR sales growth projection to 6-7%. It now expects adjusted EPS at the upper end of its $2.40–$2.50 guidance.
Recent milestones included the SAPIEN platform becoming the only TAVR approved for asymptomatic patients in both the U.S. and Europe, along with CE Mark approval for SAPIEN M3, bolstering its TMTT portfolio.
For Q3, the company anticipates revenue between $1.46 billion and $1.54 billion, and adjusted EPS ranging from $0.54 to $0.60.
